preferentially grow as colonies surrounded by a complex matrix, together called a biofilm. According to the NIH over 80% of microbial infections in the human body consist of biofilms. Biofilms are highly resistant to antibiotics and the immune system, making them difficult to treat at best, and nearly impossible to eradicate at worst. We propose to treat bacterial biofilms by simultaneous exposure to low energy, non-focused ultrasound, combined with blue/violet light (i.e. CLENS™: Coincident Light Energy and Nonfocused ultraSound). Low intensity ultrasound has previously been explored for anti-biofilm activity, however it has generally been applied in conjunction with an antibiotic. Similarly, blue/violet light has been explored as a bactericidal agent for planktonic bacteria. We hypothesized that the simultaneous application of blue/violet light with ultrasound would synergize the beneficial properties of each, and successfully provide a technologically new method to attack biofilms. A prototype laboratory device was built to deliver simultaneous ultrasound and light energy to bacterial biofilm grown in-vitro. Light emitting diodes (405nm) were used to generate 30mW/cm 2 ; and a coincident ultrasound source (450kHz) created a pressure field at less than 100mW/cm 2 . Staphylococcus epidermidis, S. aureus, and P. acnes were grown on hanging inserts (i.e. transwells) at 37°C for up to 72 hours before exposure. Following CLENS exposure, bacteria killing was quantified by serial dilution and plating on media agar. After an appropriate growth time on agar, Colony Forming Units (CFUs) were counted. Killing was dose dependent on exposure time, and could be optimized with tuning of either the light or ultrasound energy. There was >1 log10 reduction after 5 min and >3 log10 reduction after 30 min treatment (p<0.05). In comparison, 24 hr exposure to erythromycin reduced biofilm CFU by less than 1 log10 (p<0.05). While a 30 min CLENS treatment induced significant bacterial death, the die off continued to 24 hr after exposure with an additional 2 log10 reduction (p<0.05). Biofilm regrowth started at 48 hr, but after 4 additional days of growth, the biofilm had not returned to the original CFU levels (p<0.05). Importantly, the two energies must be delivered coincidentally for optimal effect. These initial results validate that the basic CLENS mechanism is effective on relevant biofilm producing bacteria: low intensity ultrasound "activates" the bacteria within the biofilm such that they become susceptible to the antimicrobial effects of blue light.
INTRODUCTION
Two of the most widespread and clinically important skin diseases are acne vulgaris and atopic dermatitis. In the US, approximately 8-10 million people are afflicted with moderate to severe (inflammatory) acne. [1] Severe acne can lead to permanent facial scarring, depression, low self-esteem, and low quality of life for patients. [1] Atopic dermatitis (AD) afflicts more than 17 million young children in the US, and often continues into adulthood. [2] The painful, burning pruritis of AD leads to discomfort, constant scratching, sleep deprivation and depression. [3] Importantly the current standard of care treatments for these two diseases are expensive, require multiple doctor visits, have associated (serious) safety issues, and are not always effective. [2, 4, 5] The billions of dollars spent each year on treatments (both prescription and OTC) for these two diseases [1, 2, 4, 6] indicate a very strong desire by patients to seek relief from symptoms. The etiology of both acne and AD is related to the presence of underlying biofilm, P. acnes or S. aureus respectively. Reduction or elimination of the biofilm will lead to relief from inflammatory symptoms. [7, 8, 9, 10, 11] Established biofilm is highly resistant to the protective action of host immune defenses and antibiotics. According to the NIH over 80% of microbial infections in the human body consist of biofilms. [12] Few drugs have specific anti-biofilm activity. [13] PhotoSonix Medical has developed a (safe) effective technology which will treat inflammatory biofilms, independent of drug resistance status, patient pregnancy concerns, or intolerance to side effects of existing drugs. The technology is CLENS™, Coincident Light Energy and Nonfocussed ultraSound. As will be described, CLENS biofilm biocidal action was demonstrated for three species of bacteria, with reduction of biofilm by 90% to over 99.9%. Of the bacteria species tested, P. acnes was the most susceptible to CLENS killing.
II. METHODS

A. Biofilm preparation
Frozen aliquots of Staphylococcus were thawed and diluted in RPMI (Roswell Park Memorial Institute medium) and 1-2 x 10 8 Colony Forming Units (CFU)/2 mL inoculated into hanging inserts [Millicell® hanging inserts (4.45 cm 2 , 0.4 μm PET, PIHT30R48, EMD Millipore)] placed in 6 well culture plates (EMD Millipore PIMWS0650) with 4 mL of RPMI at 37°C. After initial incubation, inserts with adhered bacteria were moved to new 6 well plates, refreshed with rich medium (TSB) and incubated for varying times at 37°C. The procedure was similar for P. acnes except DMEM/F10 1:1 was used for adherence, and RCM (reinforced clostridial medium) Supported in part by the National Institute of Arthritis and Musculoskeletal And Skin Diseases of the NIH under Award Number R43AR067650.
used for biofilm growth (>96 hr). Six well plates with P. acnes were placed in BD Gas Paks at 37°C. For treatment, inserts were removed from the plates and rinsed well with 4 x 0.5 mL normal saline. Biofilms were then ready for either CLENS exposure, or for biofilm staining.
B. CLENS™ Prototype
Several prototype laboratory devices were built to deliver simultaneous ultrasound and light energy to bacterial biofilm growing adherently to the membrane of a hanging insert. The CLENS prototype was designed to allow for the ultrasound transducer to be rapidly changed out, and to provide uniform light exposure across the target. Ultrasound exposure was either centered on a 4 mm 2 zone (the first prototype), or the entire surface of the insert. Figure 1 shows the latter device. Of special note is the angled chamber with a thin plastic membrane, and the container with castor oil. This approach insured that there were no ultrasound reflections which would affect the field. Figure 2 shows the ultrasound field coverage patterns; the dashed lines represent the inner diameter of the insert. The system was calibrated using a custom ultrasound measurement system [14] . By interchanging custom designed transducer elements (APC International) designed to fit into the assembly, it was possible to create matched pressure levels over a frequency range of 150kHz to 1.5MHz. The maximum pressure level was 450kPa; the pulse parameters such as pulse duration, and pulse repetition rate could be independently controlled. The LEDs had a narrow band output at 405nm; the light level was digitally controlled via laptop computer. The light output was measured by a calibrated radiometer (ILT400, International Light Technologies). 
C. Biofilm exposure and evaluation of viability
Rinsed inserts with biofilm were placed in the custom designed chamber for exposure to the CLENS device. After exposure was completed, the insert with biofilm was removed for analysis. For CFU determination, the PET membrane with attached biofilm was cut from the insert using a scalpel, and placed in 2 mL of PBS/0.2% Tween-80, followed by vigorous vortexing and sonicating in an Elma S-60H bath sonicator (Elmasonic) for 2 x 10 min at room temperature. 10 fold serial dilutions were made in PBS. Dilutions were plated onto appropriate nutrient agar plates, 100 μL per plate, >2 plates/dilution. Alternatively, for further incubation of the biofilm after exposure, the insert was returned to the 6 well plate with fresh medium. Mock treatment (biofilm placed in chamber as for exposure) did not significantly decrease CFU.
D. Statistical evaluation.
Statistical evaluation of CFU numbers was performed using GraphPad Prism v6.00 for Windows, and choosing one-way ANOVA for comparison of multiple means, or t-test for comparison of only two means. Experiments were repeated 2-3 times and representative data show.
III. RESULTS
A. Light/Ultrasound Synergy
Biofilms were cultured as described above and treated with CLENS for 30 min (250kPa, 30mW/cm 2 light). Biofilm was then stained using LIVE/DEAD to visualize the effects. Using the first prototype, light covered the entire biofilm, but the ultrasound impinged on only a 4mm diameter area centered in the light field (cf Figure 2, left) . Therefore, biofilm death from the combination of energy sources could be distinguished from light alone. As seen in Figure 3 , the biofilm was eliminated only where the two energy sources overlapped. This is visual confirmation of the synergy of light with ultrasound; in similar experiments, ultrasound alone had no visible effect on the biofilm. Synergy was confirmed in later quantified experiments involving light alone, ultrasound alone, and the combination (data not shown).
B. Quantitation of CLENS bactericidal action
A second prototype was designed and tooled in which both energies covered the entire biofilm uniformly (Figure 1; Figure  2 , right). This allowed exposure to biofilms prepared as described above, with evaluation of viability of the entire biofilm. Bacterial biofilms were prepared and CLENS treated with 456kHz@300kPa, 405nm@80mW/cm 2 , Figure 4 . Biofilms of both bacterial species were significantly reduced by CLENS treatment (p<0.0001). There was a 1 log10 reduction at 45 min for S. aureus and 1 log10 reduction at 5 min for P. acnes. The minimum limit of detection for the assay was 10 2 CFU/ biofilm and in multiple experiments the 30 min P. acnes treatment was below the lower limit of detection.
C. CLENS vs Erythromycin
CLENS exposure was next compared to an antibiotic, erythromycin (Fluka, 45703-10-F), against a P. acnes strain (6919) sensitive to erythromycin (MIC = 0.06 μg/mL). Biofilm was incubated with erythromycin for 24 hr, harvested and CFU determined. Planktonic bacteria were also treated. Alternatively P. acnes biofilm was treated with CLENS for 5, 15 or 30 min and CFU determined immediately after treatment. While extremely effective against planktonic bacteria, erythromycin was unable to reduce the P. acnes biofilm by 1 log10 (90%). This is in agreement with the reported resistance of biofilm versus planktonic P. acnes toward antibiotics. 
D. Kinetics of death/regrowth
To determine biofilm biocidal potency of an antibiotic or a drug, the minimum biofilm eradication concentration (MBEC) may be determined. [15] This value refers to the minimum drug concentration at which biofilm does not regrow after removal of the drug followed by further incubation (~24hr). CLENS does not have the same mechanism of action as drugs, however re-growth of biofilm after CLENS exposure was explored to simulate the MBEC procedure. P. acnes biofilm was exposed a single time for 30 min and either harvested for CFU determination or returned to a fresh 6 well plate for continued culture. At 24 hr post treatment fewer CFU were recovered than at 0 time post treatment (Figure 6 ). Thus a single 30 min treatment lead to an apparent continual decline over 24 hr of biofilm CFU. Fig. 6 . P. acnes biofilm bacteria ± exposure to CLENS for 30 min with either immediate plating (0 hr), or continued growth for 24 hr, and plating. Data is the % reduction compared to control untreated. Bars are the mean+/-std dev n>4, ANOVA for differences of the mean of the three determinations p<0.0001, Ttest for differences of the mean for the two treated samples, p=0.0082.
E. Effect of Utrasound Parameters
The next series of experiments were performed to explore and optimize the ultrasound parameters of CLENS for biofilm treatment, to better understand the roles of light and ultrasound. S. aureus was used for these experiments due to its much shorter doubling time versus P. acnes. For these experiments, the biofilms were exposed for 15 min and harvested immediately for CFU determination. The light level was adjusted so as to emphasize the relative ultrasound contribution. The first series of experiments involved changing the ultrasound pressure levels (Figure 7 , top) while maintaining constant ultrasound power. It was found that beyond a pressure threshold of 90kPa, there was little change in the effectiveness of the treatment (within the normal variation of biological experiments).. The second set of experiments involved changing the ultrasound frequency by 10x from 150kHz to 1.5MHz ( Figure 7 , bottom, solid line). At first, this indicated a slight tendency towards increased effectiveness at lower frequencies. However, when these data are normalized to ultrasound beam diameter (Figure 7 , bottom, dashed line), taken from measurements such as those in Figure 2 , it is seen that the variation in effectiveness is due to the variation in beam size. Thus it was concluded that frequency has little influence. Other parameters which were tested included pulse length and pulse repetition rate, and they were found to have little influence. Increasing light energy while holding ultrasound parameters constant, had a linear effect on bacterial killing.
IV. DISCUSSION AND CONCLUSIONS
This work has demonstrated that CLENS technology can successfully treat three biofilm forming bacteria (using safe, low level energy levels), and importantly, demonstrated that both energy sources are required. Table 1 provides a summary of the results for three species of bacteria tested. A reduction of >90% is considered clinically meaningful, especially for P. acnes in the treatment of acne vulgaris. The key innovation of CLENS stems from the combination of low, safe levels of light and ultrasound acting synergistically in a therapeutic manner, and combining these two energy types in a single treatment device. [16] [17] [18] The second innovation is the application of this dual energy approach to biofilms. While the scientific literature has shown that both ultrasound and light can in some respects affect bacteria and biofilms, combining the two produces a synergistic effect ideally suited to the eradication of biofilms. Low level ultrasound can affect biofilms, [19, 20, 21] and while the mechanism of action is not fully established, it involves mechanical deformation of the cellular membranes leading to increased metabolic activity. [22] Similarly, blue/violet light (400-470nm) is bactericidal in vitro, likely by interacting with porphyrins, [23] [24] [25] [26] [27] but reports demonstrating in vivo (within human skin) bactericidal activity are lacking. In general, because the bacteria within biofilms are in a metabolically depressed condition, light therapy alone is not effective. Therefore, the novelty of the CLENS approach is the simultaneous application of both treatment modalities: low intensity ultrasound "activates" the bacteria within the biofilm such that they become susceptible to the antimicrobial effects of blue light. Because CLENS uses a physical rather than a chemical (antibiotic) approach, bacteria have no natural defense mechanism, and cannot develop resistance. By keeping both energies at levels and wavelengths which have been shown or are considered safe (less than 100mW/cm 2 Ispta.0 for ultrasound; 405-427nm for light), the technology is expected to have minimal impact on normal tissue.
